|Bid||26.51 x 900|
|Ask||28.02 x 4000|
|Day's Range||27.83 - 28.19|
|52 Week Range||19.01 - 29.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.07|
Wright Medical (WMGI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On August 27, Wright Medical (WMGI) announced that it has entered a definitive merger agreement with medical device company Cartiva, a private orthopedic player, for a total cash consideration of around $435 million. Wright Medical expects the Cartiva Synthetic Cartilage Implant (or SCI) to emerge as the most profitable product for the combined company after the closure of the deal. Wright Medical is currently a leading player in the $8.0 billion global lower and upper extremities space and the biologics spaces, three of the fastest-growing areas in the orthopedic market.
Wright Medical Group's acquisition of Cartiva is expensive based on the price tag, which implies a valuation of 9.3 times 2019 estimated EV/sales, Matson said in the upgrade note. Cartiva gives Wright Medical Group immediate and direct exposure to the estimated $400-million osteoarthritis of the big toe market as it is the only approved cartilage-like polymer in the U.S., Matson said.
Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Wright intends to use the net proceeds of the offering to fund the purchase price of the previously announced pending acquisition (Acquisition) of Cartiva, Inc., as well as costs and expenses related thereto. The offering is not contingent on the closing of the Acquisition. If for any reason the Acquisition does not close, Wright intends to use the net proceeds of the offering for general corporate purposes. An automatic shelf registration statement relating to the ordinary shares offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on May 4, 2016 and was effective upon filing.
Wright Medical Group N.V. (WMGI) today announced the commencement of a registered underwritten public offering of $440 million of its ordinary shares. J.P. Morgan is acting as sole underwriter for the offering. An automatic shelf registration statement relating to the ordinary shares offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on May 4, 2016 and was effective upon filing.
NV on Monday said it reached a definitive agreement to buy orthopedic medical-device company Cartiva Inc. for $435 million in cash. Cartiva was backed by venture investors including New Enterprise Associates and Windham Venture Partners. Wright said Cartiva’s lead product, a synthetic cartilage implant for treating arthritis at the base of the great toe, received U.S. Premarket Approval in 2016.
Will Add Unique PMA-Approved Technology for High Volume Foot & Ankle Procedure and Further Accelerate Growth Opportunities in Wright’ s Extremities Business. Purchase Price of $435 Million Cash. Acquisition ...
Medical device company Wright Medical Group NV (NASDAQ: WMGI ) is likely to return to sustainable double-digit growth in the coming quarters, according to Stifel. The Analyst Analyst Mathew Blackman initiated ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Wright Medical (WMGI) delivered earnings and revenue surprises of 50.00% and 4.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Amsterdam-based company said it had a loss of 64 cents per share. Losses, adjusted for one-time gains and costs, came to 3 cents per share. The results topped Wall Street expectations. The average ...
Second Quarter 2018 Net Sales of $205 Million. Second Quarter 2018 Net Loss From Continuing Operations of $91 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $26 Million. Upper Extremities ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Wright Medical Group NV (NASDAQ: WMGI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern ...
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Veritiv ...
Stock Research Monitor: WMGI, ZBH, and ARAY LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on VRAY sign up now at www.wallstequities.com/registration . Pre-market today, WallStEquities.com ...